Quanterix Corp

Quanterix operates with a highly liquid capital structure, holding $29.3 million in cash and equivalents against total liabilities of $72.1 million, resulting in a current ratio of 10.07. The company is entirely equity-funded, with no long-term debt, and a price-to-book ratio of 0.39, indicating a significant discount to tangible asset value. Despite this liquidity, the company reported negative operating cash flow of $30.9 million and free cash flow of -$7.6 million in the latest period. Profitability remains a challenge, with a net loss of $8.4 million and an operating loss of $11.7 million, translating to a return on equity of -2.46% and return on assets of -2.03%. Gross profit of $20.2 million on $35.8 million in revenue suggests a 56.4% gross margin, but this is insufficient to offset operating expenses. The company's enterprise value to revenue of 2.82 is below the industry median for diagnostic equipment firms, reflecting its unprofitable status. Geographically, Quanterix derives 68% of revenue from North America and 32% from international markets, with no segment exceeding 15% of total revenue. The company operates a single business segment focused on its Simoa diagnostic platform, which is used in clinical and research settings for ultra-sensitive biomarker detection. Growth remains constrained, with no revenue growth reported in the latest period. The company's capital expenditures of $2.9 million were primarily directed toward maintaining its R&D infrastructure. Analysts have assigned a mean price target of $6.50, implying a 134% upside from the current market price of $2.77, but the absence of strong-buy ratings reflects uncertainty about the company's path to profitability. Risk factors include the company's reliance on a single product platform and its unprofitable operating history. The risk assessment flags low liquidity and dilution risk, but the company's negative cash flows and lack of near-term revenue growth raise concerns about long-term viability. No dilution events were detected in recent filings, and the company has not issued shares in the past 12 months. Recent 10-K filings highlight ongoing R&D investments in new assays and partnerships with clinical labs, but no material product launches or regulatory approvals were disclosed in the past quarter. The company's focus on niche biomarker detection markets may limit scalability unless it achieves broader adoption of its Simoa platform.